• Home
  • Search Results
  • In vivo redox metabolic imaging of mitochondria assesses disease progression in non-alcoholic steatohepatitis.

In vivo redox metabolic imaging of mitochondria assesses disease progression in non-alcoholic steatohepatitis.

Scientific reports (2017-12-08)
Ryosuke Nakata, Fuminori Hyodo, Masaharu Murata, Hinako Eto, Tomoko Nakaji, Takahito Kawano, Sayoko Narahara, Keiji Yasukawa, Tomohiko Akahoshi, Morimasa Tomikawa, Makoto Hashizume
ABSTRACT

Given the rising incidence of non-alcoholic fatty liver disease (NAFLD) in both adults and children, the development of a non-invasive diagnostic method for assessing disease progression to non-alcoholic steatohepatitis (NASH) has become an important research goal. Currently available non-invasive imaging technologies are only able to assess fat accumulation in the liver. Therefore, these methods are not suitable for a precise diagnosis of NASH. The standard diagnostic technique for NASH, liver biopsy, has several drawbacks, including the higher risk of complications that accompanies invasive procedures. Here, we demonstrated that in vivo mitochondrial redox metabolism was dramatically altered at an early stage, before histopathological changes, and NASH could be accurately diagnosed by in vivo dynamic nuclear polarization-magnetic resonance imaging, with carbamoyl-PROXYL as a molecular imaging probe. In addition, this technique was feasible for the diagnosis of NASH compared with histopathological findings from biopsies. Our data reveal a novel method for monitoring the dynamics of redox metabolic changes in NAFLD/NASH.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Adenosine 5′-diphosphate sodium salt, bacterial, ≥95% (HPLC)